Corvus Pharmaceuticals, Inc. (CRVS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Corvus Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Corvus Pharmaceuticals, Inc. (CRVS) has returned 90.00% so far this year and 360.06% over the past 12 months. Over the last ten years, CRVS has returned 0.26% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Mar 23, 2016, CRVS's average daily return is +0.20%, while the average monthly return is +3.99%. At this rate, your investment would double in approximately 1.5 years.

Historically, 46% of months were positive and 54% were negative. The best month was May 2023 with a return of +181.5%, while the worst month was Apr 2017 at -52.2%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 10 months.

On a daily basis, CRVS closed higher 46% of trading days. The best single day was Jan 20, 2026 with a return of +166.0%, while the worst single day was Apr 4, 2017 at -50.0%.

Corvus Pharmaceuticals, Inc. has an annualized alpha of 45.55%, beta of 0.91, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since March 24, 2016.

• This stock participated in 166.79% of S&P 500 Index downside but only 124.30% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CRVS ranks 96 for risk / return — in the top 96% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Corvus Pharmaceuticals, Inc. (CRVS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Corvus Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Corvus Pharmaceuticals, Inc. was 96.97%, occurring on Mar 28, 2023. Recovery took 705 trading sessions.

The current Corvus Pharmaceuticals, Inc. drawdown is 42.67%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Corvus Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Corvus Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.